Overview

Study of the QOL Evaluation of Trelagliptin in Patients With Type 2 Diabetes Mellitus

Status:
Completed
Trial end date:
2017-10-21
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the reduction in treatment burden during 12 weeks of trelagliptin administration in patients with type 2 diabetes on diet and exercise therapy only.
Phase:
Phase 4
Details
Lead Sponsor:
Takeda
Treatments:
Dipeptidyl-Peptidase IV Inhibitors